PL2635257T3 - Cząstki wirusopodobne (vlp) glikoproteiny wirusa wścieklizny - Google Patents

Cząstki wirusopodobne (vlp) glikoproteiny wirusa wścieklizny

Info

Publication number
PL2635257T3
PL2635257T3 PL11838942T PL11838942T PL2635257T3 PL 2635257 T3 PL2635257 T3 PL 2635257T3 PL 11838942 T PL11838942 T PL 11838942T PL 11838942 T PL11838942 T PL 11838942T PL 2635257 T3 PL2635257 T3 PL 2635257T3
Authority
PL
Poland
Prior art keywords
vlps
particles
rabies glycoprotein
glycoprotein virus
virus
Prior art date
Application number
PL11838942T
Other languages
English (en)
Inventor
Gale Smith
Ye Liu
Original Assignee
Novavax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novavax Inc filed Critical Novavax Inc
Publication of PL2635257T3 publication Critical patent/PL2635257T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/205Rhabdoviridae, e.g. rabies virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5258Virus-like particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/20011Rhabdoviridae
    • C12N2760/20111Lyssavirus, e.g. rabies virus
    • C12N2760/20134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL11838942T 2010-11-05 2011-11-07 Cząstki wirusopodobne (vlp) glikoproteiny wirusa wścieklizny PL2635257T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41076710P 2010-11-05 2010-11-05
PCT/US2011/059602 WO2012061815A2 (en) 2010-11-05 2011-11-07 RABIES GLYCOPROTEIN VIRUS-LIKE PARTICLES (VLPs)
EP11838942.8A EP2635257B1 (en) 2010-11-05 2011-11-07 RABIES GLYCOPROTEIN VIRUS-LIKE PARTICLES (VLPs)

Publications (1)

Publication Number Publication Date
PL2635257T3 true PL2635257T3 (pl) 2017-10-31

Family

ID=46025156

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11838942T PL2635257T3 (pl) 2010-11-05 2011-11-07 Cząstki wirusopodobne (vlp) glikoproteiny wirusa wścieklizny

Country Status (21)

Country Link
US (3) US9724405B2 (pl)
EP (2) EP2635257B1 (pl)
JP (2) JP6158088B2 (pl)
KR (1) KR101847908B1 (pl)
CN (2) CN103282023B (pl)
AU (1) AU2011323090B2 (pl)
BR (1) BR112013011194B1 (pl)
CA (1) CA2817005C (pl)
CY (1) CY1119284T1 (pl)
DK (1) DK2635257T3 (pl)
ES (1) ES2636965T3 (pl)
HR (1) HRP20171213T1 (pl)
HU (1) HUE034247T2 (pl)
LT (1) LT2635257T (pl)
MX (1) MX354750B (pl)
PL (1) PL2635257T3 (pl)
PT (1) PT2635257T (pl)
RS (1) RS56157B1 (pl)
SG (1) SG190140A1 (pl)
SI (1) SI2635257T1 (pl)
WO (1) WO2012061815A2 (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2615372A1 (en) 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
MX2010007962A (es) 2007-11-27 2010-11-10 Medicago Inc Particulas tipo virus de influenza recombinante (vlp) producidas en plantas transgenicas que expresan hemaglutinina.
US11446374B2 (en) 2008-12-09 2022-09-20 Novavax, Inc. Modified RSV F proteins and methods of their use
CN102307591B (zh) 2008-12-09 2016-08-03 诺瓦瓦克斯股份有限公司 修饰的rsv f蛋白及其使用方法
PL2480658T3 (pl) 2009-09-22 2017-12-29 Medicago Inc. Sposób otrzymywania VLP pochodzenia roślinnego
DK2635257T3 (en) * 2010-11-05 2017-09-04 Novavax Inc Rabies virus-like glycoprotein particles (VLP)
TWI620816B (zh) 2011-03-23 2018-04-11 苜蓿股份有限公司 植物衍生蛋白回收方法
CA2839009C (en) * 2011-06-13 2015-10-20 Medicago Inc. Rabies virus like particle production in plants
KR101479668B1 (ko) 2012-07-31 2015-01-12 대한민국 광견병 바이러스 유전자를 발현하는 재조합 아데노바이러스 및 이를 포함하는 광견병의 예방 또는 치료용 백신 조성물
CN103777021B (zh) * 2012-10-18 2016-03-02 辽宁成大生物股份有限公司 狂犬疫苗糖蛋白含量的检测方法
RU2730625C2 (ru) 2015-09-03 2020-08-24 Новавакс, Инк. Вакцинные композиции, характеризующиеся улучшенной стабильностью и иммуногенностью
CN106905434B (zh) * 2017-02-28 2021-01-26 国药中生生物技术研究院有限公司 一种包含蹄蝠肝炎病毒核心蛋白的重组融合蛋白及其制备方法和应用
WO2018161858A1 (en) 2017-03-06 2018-09-13 Guangzhou Realbenefitspot Pharmaceutical Co., Ltd. Methods of producing and characterizing virus vaccine and virus vaccine composition
EP3420076B1 (en) * 2017-03-06 2024-02-21 Guangzhou Realbenefitspot Pharmaceutical Co., Ltd. Methods of producing and characterizing virus vaccine and virus vaccine composition
BR112020008240A2 (pt) * 2017-11-06 2020-11-17 Intervet International B.V. vacina contra o vírus da raiva
KR20210004959A (ko) 2018-03-19 2021-01-13 노바백스, 인코포레이티드 다가 인플루엔자 나노입자 백신
KR102077772B1 (ko) 2018-11-29 2020-02-17 주식회사 바이오앱 광견병 예방용 백신 조성물 및 이의 제조 방법
KR102211077B1 (ko) * 2019-01-16 2021-02-02 충남대학교 산학협력단 바이러스 유사 입자를 이용한 슈도-타입 광견병 백신
CN110007080B (zh) * 2019-04-12 2022-09-23 长春西诺生物科技有限公司 一种狂犬病毒抗体定量检测试剂盒及其制备方法与检测方法
CN109959789B (zh) * 2019-04-12 2022-08-16 长春西诺生物科技有限公司 一种狂犬病毒抗体检测试纸及其制备方法与检测方法
WO2023064931A1 (en) * 2021-10-15 2023-04-20 La Jolla Institute For Immunology Engineered rabies virus glycoprotein, compositions, and methods of use thereof
CN114272367B (zh) * 2021-12-03 2023-07-07 华东理工大学 一种口服狂犬病病毒样颗粒疫苗及其制备方法
KR102566969B1 (ko) 2021-12-14 2023-08-16 안희철 근거리 통신 과정에서 충전 가능한 모바일 단말

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0237686A1 (en) 1986-03-18 1987-09-23 Institut Pasteur DNA sequences derived from the rabies virus genome
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US5667782A (en) 1992-07-16 1997-09-16 Oxford University Multiple particulate antigen delivery system
US6387373B1 (en) 1993-01-15 2002-05-14 Novavax, Inc. Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants
US5629021A (en) 1995-01-31 1997-05-13 Novavax, Inc. Micellar nanoparticles
US6589533B1 (en) * 1997-09-18 2003-07-08 Research Development Foundation Genetically-engineered alphaviruses, flaviviruses, and bunyaviruses with modified envelope transmembrane glycoproteins and altered host-range phenotype
US6673601B1 (en) * 1999-04-15 2004-01-06 Institut Pasteur Chimeric lyssavirus nucleic acids and polypeptides
AUPR011700A0 (en) * 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
JP2005515197A (ja) * 2001-12-03 2005-05-26 ドー バイオファーマ インコーポレイテッド 安定化された逆ミセル組成物およびその使用
US7211378B2 (en) * 2002-01-31 2007-05-01 Wisconsin Alumni Research Foundation Filovirus vectors and noninfectious filovirus-based particles
AU2003219760A1 (en) 2002-02-14 2003-09-04 Novavax, Inc. Optimization of gene sequences of virus-like particles for expression in insect cells
US8592197B2 (en) * 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
US9216212B2 (en) * 2005-08-05 2015-12-22 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
CA2636600A1 (en) * 2006-01-17 2007-07-26 Dnavec Corporation Novel protein expression system
US8153115B2 (en) * 2006-06-15 2012-04-10 Ben-Gurion University Of The Negev Research And Development Authority Virus-like particles for treatment of viral infections
EP2035565A4 (en) * 2006-06-30 2010-07-21 Novavax Inc METHODS OF ENHANCING THE INCORPORATION OF PROTEINS IN VIRUS-LIKE PARTICLES (VLPs)
US8980281B2 (en) 2006-09-05 2015-03-17 Academia Sinica High-yield transgenic mammalian expression system for generating virus-like particles
TW200907058A (en) * 2007-05-30 2009-02-16 Wyeth Corp Raccoon poxvirus expressing rabies glycoproteins
KR20100063030A (ko) * 2007-07-19 2010-06-10 노바백스, 인코포레이티드 바리셀라 조스터 바이러스-바이러스 유사 입자(VLPs) 및 항원
KR100961280B1 (ko) * 2008-05-21 2010-06-03 한국생명공학연구원 형광특성이 향상된 풀러렌-실리카 나노입자, 이의 제조방법및 이의 용도
WO2009153801A1 (en) * 2008-06-17 2009-12-23 Manpreet Kaur Dna vaccine based on glycoprotein gene of rabies virus conjugated to lamp-1 signal sequence at the c-terminus and an adjuvant; and method of its preparation thereof
US9296790B2 (en) 2008-10-03 2016-03-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for protein delivery
CN102307591B (zh) * 2008-12-09 2016-08-03 诺瓦瓦克斯股份有限公司 修饰的rsv f蛋白及其使用方法
DK2635257T3 (en) 2010-11-05 2017-09-04 Novavax Inc Rabies virus-like glycoprotein particles (VLP)

Also Published As

Publication number Publication date
EP2635257B1 (en) 2017-07-05
MX2013005090A (es) 2013-10-25
JP2017035093A (ja) 2017-02-16
WO2012061815A2 (en) 2012-05-10
RS56157B1 (sr) 2017-11-30
DK2635257T3 (en) 2017-09-04
EP2635257A2 (en) 2013-09-11
EP2635257A4 (en) 2014-04-02
LT2635257T (lt) 2017-09-25
CN103282023B (zh) 2018-09-21
ES2636965T3 (es) 2017-10-10
CN109157658A (zh) 2019-01-08
HRP20171213T1 (hr) 2017-10-20
EP3246019A1 (en) 2017-11-22
CY1119284T1 (el) 2018-02-14
US20180021428A1 (en) 2018-01-25
US9724405B2 (en) 2017-08-08
JP2014500013A (ja) 2014-01-09
US20190224307A1 (en) 2019-07-25
CN103282023A (zh) 2013-09-04
EP3246019B1 (en) 2021-03-03
AU2011323090A1 (en) 2013-04-04
KR20130111581A (ko) 2013-10-10
PT2635257T (pt) 2017-08-16
US10086065B2 (en) 2018-10-02
JP6195965B2 (ja) 2017-09-13
KR101847908B1 (ko) 2018-04-11
MX354750B (es) 2018-03-20
WO2012061815A3 (en) 2013-03-14
US20140178419A1 (en) 2014-06-26
SI2635257T1 (en) 2018-01-31
JP6158088B2 (ja) 2017-07-05
CA2817005C (en) 2018-09-11
HUE034247T2 (en) 2018-02-28
BR112013011194A2 (pt) 2017-06-27
RU2013125695A (ru) 2014-12-10
BR112013011194B1 (pt) 2020-12-22
SG190140A1 (en) 2013-06-28
CA2817005A1 (en) 2012-05-10
AU2011323090B2 (en) 2015-02-12

Similar Documents

Publication Publication Date Title
EP2635257A4 (en) VIRAL TYPE OF RYE GLYCOPROTEIN (VLP) PARTICLES
HRP20180706T1 (hr) Kimerna gripa nalik čestici koja sadrži hemaglutinin
IL210215A0 (en) Influenza virus-like particles (vlps) comprising hemagglutinin
EP2536428A4 (en) UNIVERSAL INFLUENZA VACCINES WITH VIRUSIC PARTICLES
EP2242510A4 (en) PSEUDO-VIRAL PARTICLES AS VACCINES FOR PARAMYXOVIRUS
HK1202442A1 (en) Vaccines against hpv hpv
HK1198703A1 (en) Hpv chimaeric particle hpv
EP2538969A4 (en) VACCINES FROM POLYSACCHARIDE PARTICLES
HK1203837A1 (en) Immunogenic hpv l2-containing vlps and related compositions and methods hpv l2 vlp
HK1200179A1 (en) Increasing virus-like particle yield in plants
EP2707480A4 (en) PSEUDOVIRAL PARTICLES (VLPs) AND PREPARATION METHOD THEREOF
EP2588135A4 (en) NANO EMULSION VACCINES
SI2739725T1 (sl) Postopek za čiščenje od virusov-podobnih delcev
EP2400982A4 (en) MULTI-ANTIGEN RELIEF SYSTEM WITH HEPATITIS E-VIRUS SIMILAR PARTICLE
EP2585598A4 (en) PAN-LYSSAVIRUS VACCINES AGAINST TOLLWUT
EP2881401A4 (en) EXTREMELY EFFICIENT METHOD OF PURIFYING VIRAL PSEUDO PARTICLES OF HUMAN PAPILLOMAVIRUS
IL220941A0 (en) Method for producing recombinant virus
IL226187A0 (en) Virus-like glycoprotein particles